Murakami, NaokaBorges, Thiago J.Yamashita, MichifumiRiella, Leonardo2016-07-142016Murakami, Naoka, Thiago J. Borges, Michifumi Yamashita, and Leonardo V. Riella. 2016. “Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma.” Clinical Kidney Journal 9 (3): 411-417. doi:10.1093/ckj/sfw024. http://dx.doi.org/10.1093/ckj/sfw024.2048-8505http://nrs.harvard.edu/urn-3:HUL.InstRepos:27662090Immune-checkpoint inhibitors are emerging as revolutionary drugs for certain malignancies. However, blocking the co-inhibitory signals may lead to immune-related adverse events, mainly in the spectrum of autoimmune diseases including colitis, endocrinopathies and nephritis. Here, we report a case of a 75-year-old man with metastatic malignant melanoma treated with a combination of nivolumab (anti-PD1-antibody) and ipilimumab (anti-CTLA-4 antibody) who developed systemic rash along with severe acute tubulointerstitial nephritis after two doses of combination therapy. Kidney biopsy and peripheral blood immune profile revealed highly proliferative and cytotoxic T cell features. Herein, we discuss the pathophysiology and management of immune checkpoint blockade-related adverse events.en-USacute kidney injuryimmune-checkpoint blockadeinterstitial nephritisJournal Article2016-07-1410.1093/ckj/sfw024